Anna Laurell

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Kheir, Alaa; Johannsdottir, Berglind; Gronn-Weiss, Alexandra; Liu, Lisa L. et al.

Part of Acta Oncologica, p. 1355-1364, 2025

• DOI for Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab
• Download full text (pdf) of Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

Holmsten, Karin; Eknert, Johanna; Ofverholm, Elisabeth; Papantoniou, Dimitrios et al.

Part of Clinical Genitourinary Cancer, 2023

• DOI for Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
• Download full text (pdf) of Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

Lindberg, Åsa; Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne et al.

Part of Hematological Oncology, p. 23-31, 2022

• DOI for Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience
• Download full text (pdf) of Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres

Stenman, Maria; Staehler, Michael; Szabados, Bernadett; Sandström, Per et al.

Part of Acta Oncologica, p. 306-312, 2019

• DOI for Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres
• Download full text (pdf) of Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne; Laurell, Anna et al.

Part of Haematologica, 2018

• DOI for Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
• Download full text (pdf) of Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Kheir, Alaa; Johannsdottir, Berglind; Gronn-Weiss, Alexandra; Liu, Lisa L. et al.

Part of Acta Oncologica, p. 1355-1364, 2025

• DOI for Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab
• Download full text (pdf) of Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

Holmsten, Karin; Eknert, Johanna; Ofverholm, Elisabeth; Papantoniou, Dimitrios et al.

Part of Clinical Genitourinary Cancer, 2023

• DOI for Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
• Download full text (pdf) of Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

Lindberg, Åsa; Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne et al.

Part of Hematological Oncology, p. 23-31, 2022

• DOI for Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience
• Download full text (pdf) of Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres

Stenman, Maria; Staehler, Michael; Szabados, Bernadett; Sandström, Per et al.

Part of Acta Oncologica, p. 306-312, 2019

• DOI for Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres
• Download full text (pdf) of Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne; Laurell, Anna et al.

Part of Haematologica, 2018

• DOI for Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
• Download full text (pdf) of Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Jerkeman, Mats; Eskelund, Christian Winther; Hutchings, Martin; Raty, Riikka et al.

Part of Tha Lancet Haematology, 2018

• DOI for Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.

Laurell, Anna; Lönnemark, Maria; Brekkan, Einar; Magnusson, Anders et al.

Part of Journal for ImmunoTherapy of Cancer, 2017

• DOI for Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
• Download full text (pdf) of Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Kolstad, Arne; Pedersen, Lone Bredo; Eskelund, Christian W.; Husby, Simon et al.

Part of Biology of blood and marrow transplantation, p. 428-435, 2017

• DOI for Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

Hellström, Vivan; Tufveson, Gunnar; Wallgren, AnnaCarin; Loskog, Angelica et al.

Part of American Journal of Transplantation, p. 472-472, 2017

• DOI for Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

Eskelund, Christian W.; Kolstad, Arne; Jerkeman, Mats; Raty, Riikka et al.

Part of British Journal of Haematology, p. 410-418, 2016

• DOI for 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Albertsson-Lindblad, Alexandra; Kolstad, Arne; Laurell, Anna; Raty, Riikka et al.

Part of Blood, p. 1814-1820, 2016

• DOI for Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study

Hellström, Vivan; Enström, Ylva; von Zur-Mühlen, Bengt; Hagberg, Hans et al.

Part of Acta Oncologica, p. 774-781, 2016

• DOI for Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials

Hoster, E.; Geisler, C. H.; Doorduijn, J.; van der Holt, B. et al.

Part of Leukemia, p. 1428-1430, 2016

• DOI for Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Husby, Simon; Ralfkiaer, Ulrik; Garde, Christian; Zandi, Roza et al.

Part of Blood, p. 2669-2677, 2015

• DOI for miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Long-term survival in unfavorable-risk mRCC patients after intratumoral administration of a cell-based allogeneic vaccine adjuvant.

Magnusson, Anders; Wallgren, AnnaCarin; Brekkan, Einar; Lönnemark, Maria et al.

Part of Journal of Clinical Oncology, 2015

Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

Farnebo, Jacob; Gryback, Per; Harmenberg, Ulrika; Laurell, Anna et al.

Part of BMC Cancer, p. 408, 2014

• DOI for Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
• Download full text (pdf) of Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma

Stenman, Maria; Laurell, Anna; Lindskog, Magnus

Part of Medical Oncology, p. 841, 2014

• DOI for Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma

Nordic MCL-3 study: ⁹⁰Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Kolstad, Arne; Laurell, Anna; Jerkeman, Mats; Grønbæk, Kirsten et al.

Part of Blood, p. 2953-2959, 2014

• DOI for Nordic MCL-3 study: ⁹⁰Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

Laurell, Anna; Kolstad, Arne; Jerkeman, Mats; Raty, Riikka et al.

Part of Leukemia and Lymphoma, p. 1206-1208, 2014

• DOI for High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma: a Nordic Lymphoma Group study

Nordström, Lena; Sernbo, Sandra; Eden, Patrik; Grønbaek, Kirsten et al.

Part of British Journal of Haematology, p. 98-108, 2014

• DOI for SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma: a Nordic Lymphoma Group study

One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

Tandstad, T.; Stahl, O.; Hakansson, U.; Dahl, O. et al.

Part of Annals of Oncology, p. 2167-2172, 2014

• DOI for One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials

Husby, Simon; Pedersen, Lone Bredo; Ralfkiaer, Ulrik; Garde, Christian et al.

Part of Blood, 2014

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur

Geisler, Christian H.; Kolstad, Arne; Laurell, Anna; Jerkeman, Mats et al.

Part of British Journal of Haematology, p. 355-362, 2012

• DOI for Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur

High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer: a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA)

Haugnes, Hege S.; Laurell, Anna; Stierner, Ulrika; Bremnes, Roy M. et al.

Part of Acta Oncologica, p. 168-176, 2012

• DOI for High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer: a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA)

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

Arne, Kolstad; Laurell, Anna; Jerkeman, Mats; Gronbaek, Kirsten et al.

Part of Blood, p. 747, 2012

Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group

Olofsson, Sven-Erik; Tandstad, Torgrim; Jerkeman, Mats; Dahl, Olav et al.

Part of Journal of Clinical Oncology, p. 2032-2039, 2011

• DOI for Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group

Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group

Tandstad, Torgrim; Smaaland, Rune; Solberg, Arne; Bremnes, Roy M. et al.

Part of Journal of Clinical Oncology, p. 719-725, 2011

• DOI for Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group

Impact of TP53 mutation and 17p deletion in mantle cell lymphoma

Halldórsdóttir, Anna Margret; Lundin, A; Murray, Fiona; Mansouri, Larry et al.

Part of Leukemia, 2011

• DOI for Impact of TP53 mutation and 17p deletion in mantle cell lymphoma

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Geisler, Christian H.; Kolstad, Arne; Laurell, Anna; Räty, Riikka et al.

Part of Blood, p. 1530-1533, 2010

• DOI for The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Hess, Georg; Herbrecht, Raoul; Romaguera, Jorge; Verhoef, Gregor et al.

Part of Journal of Clinical Oncology, p. 3822-3829, 2009

• DOI for Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Genome-wide microarray-based comparative genomic hybridization analysis of lymphoplasmacytic lymphomas reveals heterogeneous aberrations

Buckley, Patrick G.; Walsh, Sarah H.; Laurell, Anna; Sundström, Christer et al.

Part of Leukemia and Lymphoma, p. 1528-34, 2009

• DOI for Genome-wide microarray-based comparative genomic hybridization analysis of lymphoplasmacytic lymphomas reveals heterogeneous aberrations

Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma

Flordal Thelander, Emma; Ichimura, Koichi; Collins, V. Peter; Walsh, Sarah H. et al.

Part of Leukemia Research, p. 1219-1230, 2007

• DOI for Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma

Telomere length and correlation with histopathogenesis in B-cell leukemias/lymphomas

Walsh, Sarah H.; Grabowski, Pawel; Berglund, Mattias; Thunberg, Ulf et al.

Part of European Journal of Haematology, p. 283-289, 2007

• DOI for Telomere length and correlation with histopathogenesis in B-cell leukemias/lymphomas

Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14).

Adde, Magdalena; Enblad, Gunilla; Hagberg, Hans; Sundström, Christer et al.

Part of Med Oncol, p. 283-93, 2006

Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status.

Thorselius, Mia; Kröber, Alexander; Murray, Fiona; Thunberg, Ulf et al.

Part of Blood, p. 2889-94, 2006

Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or V(H) gene mutation status in chronic lymphocytic leukaemia.

Tobin, Gerard; Skogsberg, Åsa; Thunberg, Ulf; Laurell, Anna et al.

Part of Leukemia, p. 871-873, 2005

Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status.

Grabowski, Pawel; Hultdin, Magnus; Karlsson, Karin; Tobin, Gerard et al.

Part of Blood, p. 4807-12, 2005

Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes.

Thelander, Emma Flordal; Walsh, Sarah H; Thorselius, Mia; Laurell, Anna et al.

Part of Mod Pathol, p. 331-9, 2005

Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.

Tobin, Gerard; Thunberg, Ulf; Laurell, Anna; Karlsson, Karin et al.

Part of Haematologica, p. 465-9, 2005

Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia.

Tobin, Gerard; Thunberg, Ulf; Karlsson, Karin; Murray, Fiona et al.

Part of Blood, p. 2879-85, 2004

VH gene mutation status and cellular drug resistance in chronic lymphocytic leukemia

Åleskog, Anna; Tobin, Gerard; Laurell, Anna; Thunberg, Ulf et al.

Part of Eur J Haematol, p. 407-411, 2004